학술논문
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial
Document Type
Article
Author
Shi, Yuankai ; Bi, Minghong ; Li, Qingshan ; Wang, Guolei ; Chen, Jianhua ; Li, Mingjun ; Shi, Jianhua ; Mei, Jiazhuan ; Ji, Yinghua ; Xia, Qingdi ; Feng, Yuanqing ; Xu, Shufeng ; Zhang, Tongmei ; Gao, Xiaohui ; Tang, Shubin ; Weng, Jie ; Cao, Zhuo ; Wu, Hongbo ; Ren, Xiubao ; Xie, Hua ; Liu, Hua ; Liu, Qiang ; Yin, Xing ; Luo, Xiaoyong ; Chen, Jun ; Zhang, Haiming ; Guo, Zhiyuan ; Ding, Cuimin ; Jin, Xin ; Sun, Rongli ; Yang, Sheng
Source
In Cancer Pathogenesis and Therapy January 2025
Subject
Language
ISSN
2949-7132
Abstract
@@@@Highlights •SIBP04 is a biosimilar of bevacizumab (Avastin®)•Efficacy and safety of SIBP04 were equivalent to Avastin®’s in non-squamous non-small-cell lung cancer (nsqNSCLC)•SIBP04 plus paclitaxel and carboplatin will offer an alternative first-line treatment option for nsqNSCLC.